drugset
drugset / Trial / NCT04645797

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

NCT04645797 ↗

Phase 1 Terminated 11 enrolled Apros Therapeutics, Inc
NaSequentialOpen-labelTreatment

Summary

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

Timeline

Start
2021-01-19
Primary completion
2022-05-07
Completion
2022-05-07

Outcome

Outcome not reported

Stopped: “Study terminated prematurely due to internal corporate decision”

Publications

  • Background Miller A, Le T, Holland J, et al1167 APR003, an oral liver- and GI-targeted TLR7 agonist, elicits a robust type I interferon response in advanced colorectal cancer patientsJournal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1167

Drugs

EvaluationDrugModalityDoseRoute
Subject APR003 Small molecule — —

Indications

colorectal carcinoma